EconTalk Richard Epstein on Property Rights and Drug Patents
17 snips
Feb 19, 2007 
Richard Epstein, a law scholar at the University of Chicago and Hoover Institution, discusses property rights, patents, and drug regulation. He compares physical and intellectual property. He explains how patents incentivize risky pharma innovation and how regulatory delays and third-party payers shape drug markets. He also explores FDA roles, counterfeit risks from reimportation, and alternatives to blanket bans.
AI Snips
Chapters
Books
Transcript
Episode notes
Development Costs And FDA Delay Squeeze Drug Patents
- Pharma patents face two key problems: extremely high development costs and long regulatory delays.
- New molecular entities can cost ~$1 billion and FDA approvals can eat 8–10 years, shrinking effective patent market life.
Statutory Patents Translate To Much Shorter Market Life
- Effective patent life for many drugs is far below statutory 20 years due to pre-approval time and capital costs.
- Hatch-Waxman offers limited extension, but clinical trial duration and cost of capital still reduce market exclusivity to ~8–9 years.
Third Party Payers Distort Drug Price Signals
- Third-party payment and insurer bargaining change price signals and raise net profitability for drugs.
- Insurers use formularies and bulk negotiations to steer uptake, creating many different transaction prices across buyers.
